From: A comparison of biologicals in the treatment of adults with severe asthma – real-life experiences
Anti-IL5/IL5R (Reslizumab, Mepolizumab, Benralizumab) | N = 38 | Anti-IgE (Omalizumab) | N = 17 | |||
---|---|---|---|---|---|---|
Baseline | Change | P | Baseline | Change | P | |
Courses of OCS (number/year) a | 1.24 (0–8. SD 2.03) | −0.79 (−8–2. SD 2.14) | 0.031 | 0.82 (0–3. SD 1.04) | −0.59 (−3–1. SD 1.03) | 0.037 |
Courses of antibiotics (number/year) | 0.94 (0–5. SD 1.26) | 0.12 (−4–5. SD 1.99) | 0.718 | 1.12 (0–4. SD 1.23) | −0.22 (− 3–7. SD 2.09) | 0.674 |
Polypectomy (number) | 1.37 (0–20. SD 3.29) | −1.24 (−20–1. SD 3.30) | 0.028 | 1.59 (0–20. SD 4.67) | −1.41 (− 20–1. SD 4.69) | 0.246 |
Ethmoidectomy (number) | 0.76 (0–4. SD 0.87) | −0.71 (− 4–1. SD 0.94) | 5.10 e− 05 | 0.29 (0–1. SD 0.46) | −0.12 (− 1–2. SD 0.68) | 0.496 |
FESS (number) b | 1.03 (0–4. SD 0.87) | − 0.95 (− 3–1. SD 0.89) | 1.34 e− 07 | 1.12 (0–4. SD 1.13) | −0.82 (− 4–1. SD 1.25) | 0.018 |
Polyps in nasal inspection (number, (%)) | 22 (58) | −9 | 0.038 | 7 (41) | −1 | 0.724 |
Mucous oedema in nasal inspection (number, (%)) | 19 (50) | −12 | 0.004 | 7 (41) | + 4 | 0.169 |